Abstract
Lactoferrin (LF) is a member of the transferring family with a molecular weight of 78-kDa and is present in numerous external secretions including human milk, saliva, tears, airway mucus, and the secondary granules of neutrophils [1]. It is an iron-binding glycoprotein found in abundance in premature milk with its concentration decreasing as the term age [2]. This protein has been establish to cause a number of biological roles, including antimicrobial (Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus mutans, Pseudomonas aeruginosa, Haemophilus influenzae, Helicobacter pylori, Clostridium difficile, Shigella Flexnieria) anti-fungal (Candida albicans), anti-cancer (head and neck squamous cell carcinoma), anti-viral (HCV, HIV) antioxidant, and immunomodulatory effects [3]. Partial degradation of LF by pepsin enzyme give rise to peptides termed lactoferricin (LFcin) with most potent antimicrobial action [4].
Highlights
Lactoferrin (LF) is a member of the transferring family with a molecular weight of 78-kDa and is present in numerous external secretions including human milk, saliva, tears, airway mucus, and the secondary granules of neutrophils [1]
The writers concluded that compared with placebo, Bovine lactoferrin (BLF) supplementation alone or in combination with Lactobacillus rhamnosus GG (LGG) reduced the incidence of a first episode of late-onset sepsis in VLBW neonates [8]
The writers concluded that prophylactic oral administration of Neonatal sepsis and Necrotizing enterocolitis (NEC) are very BLF reduced the incidence of IFI in preterm VLBW neonates [9]
Summary
Lactoferrin (LF) is a member of the transferring family with a molecular weight of 78-kDa and is present in numerous external secretions including human milk, saliva, tears, airway mucus, and the secondary granules of neutrophils [1]. Outcomes of the survey were very bright with an incidence of LOS significantly reduced in the BLF and BLF plus LGG groups (9/153 [5.9%] and 7/151 [4.6%], respectively) when compared with the control group receiving placebo (29/168 [17.3%]) (RR, 0.34; 95% CI, 0.17-0.70; P= 0.002 for BLF vs control and RR, 0.27; 95% CI, 0.12-0.60; P< 0.001 for BLF plus LGG vs control).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
